[1] JUSTIN J.J. LEAHY . Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries[J]. Bioorganic & Medicinal Chemistry Letters, 2004, 14 24: Pages 6083-6087. DOI:
10.1016/j.bmcl.2004.09.060[2] IAN R. HARDCASTLE. Discovery of Potent Chromen-4-one Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) Using a Small-Molecule Library Approach[J]. Journal of Medicinal Chemistry, 2005, 48 24: 7829-7846. DOI:
10.1021/jm050444b[3] YAN ZHAO. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.[J]. Cancer research, 2006, 66 10: 5354-5362. DOI:
10.1158/0008-5472.can-05-4275[4] WOJCIECH M CISZEWSKI. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.[J]. Breast Cancer Research and Treatment, 2014, 143 1: 47-55. DOI:
10.1007/s10549-013-2785-6[5] CHUANJIE YANG. NU7441 Enhances the Radiosensitivity of Liver Cancer Cells.[J]. Cellular Physiology and Biochemistry, 2016, 38 5: 1897-1905. DOI:
10.1159/000445551[6] WEI GENG. DNA‑PKcs inhibitor increases the sensitivity of gastric cancer cells to radiotherapy.[J]. Oncology reports, 2019, 42 2: 561-570. DOI:
10.3892/or.2019.7187